Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Changes in three tumor markers in patients with advanced lung adenocarcinoma after combination therapy with pemetrexed and platinum: Short-term treatment efficacy

Yang Lou, Bo Xu, Xianshuai Li, Xiaoyi Xu, Xianguo Chen

Cardiothoracic Surgery Department, JinHua Hospital of ZheJiang University, JinHua Municipal Central Hospital, No. 365 Renmin East Road, Jinhua, Zhejiang 321000, China;

For correspondence:- Xianguo Chen Email: jz1183@163.com

Accepted: 27 February 2019 Published: 31 March 2019

Citation: Lou Y, Xu B, Li X, Xu X, Chen X. Changes in three tumor markers in patients with advanced lung adenocarcinoma after combination therapy with pemetrexed and platinum: Short-term treatment efficacy. Trop J Pharm Res 2019; 18(3):619-623 doi: 10.4314/tjpr.v18i3.25

© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study changes in three tumor markers before and after combination treatment with pemetrexed and platinum, and evaluate the short-term therapeutic effectiveness of the treatment in advanced lung adenocarcinoma (ALA) subjects.

Methods: Patients with ALA (n =120) admitted to JinHua Municipal Central Hospital from January 2017 to May 2018 were selected as the research subjects. According to the results of chemotherapy, they were divided into two groups: significantly-reduced tumor volume group (90 cases), and non-significantly-reduced tumor volume group (21 cases). The two groups were treated with chemotherapy using a combination of pemetrexed and cisplatin. The levels of CEA, CA125 and CYFRA21-1 before and after chemotherapy were assayed to determine their relationship with short-term therapy effectiveness.

Result: Overall analysis of tumor markers in the 120 patients with ALA showed statistically significant reduction in overall tumor marker levels before and after chemotherapy (p < 0.05). At the end of chemotherapy, the tumor markers were markedly reduced in subjects with significant tumor volume, and there was statistical difference between the two groups before chemotherapy (p < 0.05). Changes in CEA, CA125 and CYFRA21-1 were positively correlated with the chemotherapeutic effects on patients with ALA.

Conclusion: In ALA patients treated with pemetrexed and platinum, changes in serum CEA, CA125 and CYFRA21-1 profiles before and after treatment depend on the effect of chemotherapy, and they are reliable for prediction of short-term therapeutic efficacy.

Keywords: CEA, CA125, CYFRA21-1, Lung adenocarcinoma, Short-term efficacy